BioCryst Pharmaceuticals is trading at $9.63, with a -4.37% move on August 20, 2026, amid biotech profit-taking after the previous session’s Moderna-driven rally.
- Biotech sector is down 2.47% in regular trading; broader markets are lower as Treasury yields rebound.
- Reuters said Moderna fell 11.4% after its sharp prior-session surge, reinforcing sector-wide profit-taking.
- No new company-specific announcement, earnings report, regulatory decision, or analyst action was identified on August 20, 2026; latest major update: August 5 quarterly release.